WHO WE ARE
OUR SCIENCE
Retinol is produced in the liver, and retinol binding protein 4 (RBP4) carries retinol through the bloodstream from the liver to the eyes. Tinlarebant, developed from our RBP4 intellectual property portfolio, is a novel, once-a-day oral therapy aimed at reducing and then maintaining the lower level of RBP4 in the patient. In doing that, less retinol is delivered to the eye. Ultimately, by modulating the amount of retinol entering the eye, Tinlarebant could reduce the formation of vision-damaging toxins. In clinical trials, Tinlarebant has demonstrated target specificity and potency that we believe could be clinically meaningful to treat people living with 吉祥坊体育 and GA.
OUR RESEARCH
Tinlarebant has been granted Orphan Drug Designation in the United States, Europe and Japan as well as Rare Pediatric Disease (RPD) designation and Fast Track Designation (FTD) in the U.S and Sakigake (Pioneer Drug) Designation in Japan.
For the most recent news on our clinical trial progress, visit our Press Release section.
OUR TEAM
Our leadership team is comprised of individuals with significant expertise in ophthalmology drug discovery and development.